PALB2 and breast carcinoma: Rahman and colleagues identified PALB2 monoallelic truncating variants in ~1% of patients with hereditary breast cancer (9) [as confirmed by Fernandes et al. (22)], whose risk of developing breast cancer was 2.3-fold higher than the risk observed amid controls.